Alnylam have a long history of developing the therapeutic potential of RNAi technology. In particular their platform is focused on mRNAs expressed in hepatocytes, utilizing a specific hepatocyte interaction for drug targeting. This seminar will outline their approach and product pipeline, with a view to discussing potential collaboration.
This seminar is for anyone with a broad interest in RNAi technology.